Seroprevalence and preventive practices of dengue and chikungunya among school children in Bangkok: Gaps in prevention and vaccination strategies

Background Dengue and chikungunya, both transmitted by Aedes mosquitoes, continue to pose significant public health concerns in Thailand, particularly during the rainy season. Despite ongoing vector control efforts, the incidence of infection remains high, with an increasing trend observed in chikungunya. This underscores the need for additional control measures, including vaccination, to reduce disease burden and morbidity. This study aims to assess the seroprevalence of dengue and chikungunya infections among children aged 10–15 years in Bangkok and to evaluate the knowledge, attitudes, and practices (KAP) related to mosquito-borne disease prevention. Methodology A cross-sectional descriptive study was conducted across 12 schools in Bangkok. Children aged 10–15 years were included. Seroprevalence was determined using rapid diagnostic tests (Abbott DENGUE IgG/IgM and Citest Chikungunya IgG/IgM) based on the immunochromatography technique, using fingertip blood samples. Parents completed KAP questionnaires, including factors influencing vaccination decisions. Principal findings From June to August 2024, 937 participants were enrolled, with a mean (SD) age of 11 (1.6) years; 67% were aged 10–12 years, and 33% were aged 13–15 years. The seroprevalence of dengue was 28.1% (95% CI 25.2-31.0), while that of chikungunya was 6.3% (95% CI 4.7-7.9). KAP assessments revealed a high level of awareness regarding symptoms and transmission; however, notable deficiencies in preventive behaviors were identified. Only 14.8% of respondents reported consistent use of mosquito repellent, and 17.5% routinely inspected and removed mosquito larvae from their homes. Conclusion The substantial seroprevalence of dengue and the emerging trend of chikungunya among children in Bangkok highlights the urgent need to enhance community education and strengthen vector control interventions. Expanding dengue vaccination coverage and raising awareness about chikungunya prevention, including consideration for future vaccine implementation, are essential to mitigating future outbreaks and reducing the disease burden. Trial registration Thai Clinical Trials under the number TCTR20240404002 ( https://www.thaiclinicaltrials.org/show/TCTR20240404002 ).